Physician profile
Reena Lepine
NPI 1194004085
$3,028.51
in general payments reported to CMS, 2019-2025
5 companies · $666 in 2025
The $666 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $19.40 · 2022: $488 · 2023: $666 · 2024: $676 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600 · Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
| Food and Beverage | $208.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,033.09 | 2019-2025 | Acuvue |
| Coopervision INC. | $981.35 | 2019-2025 | Clariti Contact Lens |
| Alcon Vision LLC | $981.34 | 2019-2025 | Air Optix |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genzyme Corporation | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Lepine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.